Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

ABSTRACT: Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

PROVIDER: PRJNA1010685 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25788800_1.fastq.gz	Fastqsanger.gz
	SRR25788800_2.fastq.gz	Fastqsanger.gz
	SRR25788801_1.fastq.gz	Fastqsanger.gz
	SRR25788801_2.fastq.gz	Fastqsanger.gz
	SRR25788802_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 100

Similar Datasets

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CART]

Project description:Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CART]

| PRJNA1010218 | ENA

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [Pilot_Data]

Project description:Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [Pilot_Data]

| PRJNA1010220 | ENA

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CROPSeq_Data]

Project description:Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CROPSeq_Data]

| PRJNA1010684 | ENA

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [Pilot_Data]

Project description:CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced chromosome loss is a universal phenomenon and evaluate its clinical significance, we conducted a systematic analysis in primary human T cells. Arrayed and pooled CRISPR screens revealed that chromosome loss was generalizable across the genome and resulted in partial and entire loss of the chromosome, including in pre-clinical chimeric antigen receptor T cells. T cells with chromosome loss persisted for weeks in culture, implying the potential to interfere with clinical use. A modified cell manufacturing process, employed in our first-in-human clinical trial of Cas9-engineered T cells, dramatically reduced chromosome loss while largely preserving genome editing efficacy. Expression of p53 correlated with protection from chromosome loss observed in this protocol, suggesting both a mechanism and strategy for T cell engineering that mitigates this genotoxicity in the clinic.

2023-11-18 | GSE241839 | GEO

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CART]

2023-11-18 | GSE241838 | GEO

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CROPSeq_Data]

2023-11-18 | GSE241882 | GEO

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells.

Project description:CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced chromosome loss is a universal phenomenon and evaluate its clinical significance, we conducted a systematic analysis in primary human T cells. Arrayed and pooled CRISPR screens revealed that chromosome loss was generalizable across the genome and resulted in partial and entire loss of the chromosome, including in pre-clinical chimeric antigen receptor T cells. T cells with chromosome loss persisted for weeks in culture, implying the potential to interfere with clinical use. A modified cell manufacturing process, employed in our first-in-human clinical trial of Cas9-engineered T cells, 1 dramatically reduced chromosome loss while largely preserving genome editing efficacy. Expression of p53 correlated with protection from chromosome loss observed in this protocol, suggesting both a mechanism and strategy for T cell engineering that mitigates this genotoxicity in the clinic.

| S-EPMC10055432 | biostudies-literature

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells.

Project description:CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced chromosome loss is a universal phenomenon and evaluate its clinical significance, we conducted a systematic analysis in primary human T cells. Arrayed and pooled CRISPR screens revealed that chromosome loss was generalizable across the genome and resulted in partial and entire loss of the targeted chromosome, including in preclinical chimeric antigen receptor T cells. T cells with chromosome loss persisted for weeks in culture, implying the potential to interfere with clinical use. A modified cell manufacturing process, employed in our first-in-human clinical trial of Cas9-engineered T cells (NCT03399448), reduced chromosome loss while largely preserving genome editing efficacy. Expression of p53 correlated with protection from chromosome loss observed in this protocol, suggesting both a mechanism and strategy for T cell engineering that mitigates this genotoxicity in the clinic.

| S-EPMC10664023 | biostudies-literature

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-11-18 | GSE241683 | GEO

Engineered CRISPR-Cas9 for Streptomyces sp. genome editing

Project description:Engineered CRISPR-Cas9 for Streptomyces sp. genome editing

| PRJEB79564 | ENA